EndoQuest Robotics, a leader in endoluminal robotic surgical technology, has successfully completed a Series D-2 financing round to advance its flexible surgical platform. This funding will support the pivotal PARADIGM clinical trial, expedite U.S. FDA clearance, and enhance early feasibility studies in the upper gastrointestinal tract. The round was co-led by Crescent Enterprises and Dr. Fred Moll, with contributions from Puma Venture Capital and UTHealth Houston.
The ongoing PARADIGM Trial (Prospective Assessment of a Robotic Assisted Device in Gastrointestinal Medicine) has reached a milestone, with Dr. Eric Haas at HCA Houston Healthcare Medical Center completing two successful colorectal endoscopic submucosal dissection (ESD) procedures using the Endoluminal Surgical (ELS) System. These procedures demonstrated the ELS System’s ability to treat complex lesions that would normally require more invasive surgery. The IDE-approved study aims to enroll 50 patients across five prominent U.S. hospitals and will assess the safety and effectiveness of the ELS System.
EndoQuest plans to seek market authorization for the ELS System in the United States upon trial completion. *Lesion characteristics are provided for descriptive purposes only and do not indicate clinical outcomes.
KEY QUOTES:
“EndoQuest has developed a groundbreaking capability that could revolutionize how procedures are performed in robotic endoscopic surgery.” A recognized pioneer in the field, Dr. Moll went on to say, “I observed the first clinical cases which were very impressive with regard to the novel capabilities of the system.”
Dr. Moll
“EndoQuest perfectly fits our investment thesis of targeting high-CAGR surgical robotics fields where robotic solutions can verticalize and capture value across the entire operating theater. We focus on companies that operate in surgical theaters where there is no presence from incumbents, and EndoQuest’s endoluminal platform exemplifies this. We are also highly encouraged by the strong interest from strategic partners, which further validates our confidence in EndoQuest’s vision and its potential to reshape surgical care.”
Neeraj Agrawal, Executive Director of Crescent Enterprises and Director at EndoQuest
“Our team is laser-focused on delivering four key pillars of value as we advance our platform. These include stellar clinical data from our trials, an attractive pathway to FDA clearance, progression of the world’s most advanced endoluminal visualization systems, and the pioneering of new upper GI clinical procedures in parallel with our ongoing IDE trial. Through focused execution across these four pillars, we are working to bring the impact of our pioneering technology to patients and physicians worldwide.”
Eduardo Fonseca, EndoQuest Robotics Interim CEO
“Building on strong momentum and a rapidly expanding technology portfolio with high-impact clinical applications, we are positioned to deliver meaningful long-term returns for our investors. Across both our U.S. and Korea campuses, we remain committed to capital discipline and focused execution.”
Nicholas Drysdale, EndoQuest Robotics Chief Financial Officer
